278 related articles for article (PubMed ID: 26285615)
21. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
Lee HZ; Miller BW; Kwitkowski VE; Ricci S; DelValle P; Saber H; Grillo J; Bullock J; Florian J; Mehrotra N; Ko CW; Nie L; Shapiro M; Tolnay M; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2014 Aug; 20(15):3902-7. PubMed ID: 24824310
[TBL] [Abstract][Full Text] [Related]
22. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
[TBL] [Abstract][Full Text] [Related]
23. Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia.
Small S
Clin Adv Hematol Oncol; 2013 Dec; 11(12):809-10. PubMed ID: 25016628
[No Abstract] [Full Text] [Related]
24. Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.
Bourrier N; Landego I; Bucher O; Squires M; Streu E; Hibbert I; Whiteside T; Gibson SB; Geirnaert M; Johnston JB; Dawe DE; Banerji V
BMC Cancer; 2022 Feb; 22(1):148. PubMed ID: 35123433
[TBL] [Abstract][Full Text] [Related]
25. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
26. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.
Freeman CL; Morschhauser F; Sehn L; Dixon M; Houghton R; Lamy T; Fingerle-Rowson G; Wassner-Fritsch E; Gribben JG; Hallek M; Salles G; Cartron G
Blood; 2015 Dec; 126(24):2646-9. PubMed ID: 26447188
[No Abstract] [Full Text] [Related]
27. Obinutuzumab in hematologic malignancies: lessons learned to date.
Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
[TBL] [Abstract][Full Text] [Related]
28. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
Tobinai K; Klein C; Oya N; Fingerle-Rowson G
Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
[TBL] [Abstract][Full Text] [Related]
29. Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
Said R; Tsimberidou AM
Expert Opin Biol Ther; 2017 Nov; 17(11):1463-1470. PubMed ID: 28893099
[TBL] [Abstract][Full Text] [Related]
30. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
Robak T; Blonski JZ; Robak P
Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
Klein C; Bacac M; Umana P; Fingerle-Rowson G
Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
[TBL] [Abstract][Full Text] [Related]
32. Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab.
Reslan L; Dalle S; Herveau S; Perrial E; Dumontet C
Leuk Lymphoma; 2014 Jan; 55(1):188-90. PubMed ID: 23537278
[No Abstract] [Full Text] [Related]
33. Obinutuzumab for the treatment of indolent lymphoma.
Edelmann J; Gribben JG
Future Oncol; 2016 Aug; 12(15):1769-81. PubMed ID: 27117452
[TBL] [Abstract][Full Text] [Related]
34. [Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia in 2015].
Obrtlíková P; Urbanová R
Klin Onkol; 2015; 28 Suppl 3():3S22-9. PubMed ID: 26489498
[TBL] [Abstract][Full Text] [Related]
35. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.
Bagacean C; Zdrenghea M; Tempescul A; Cristea V; Renaudineau Y
Immunotherapy; 2016 May; 8(5):569-81. PubMed ID: 27140410
[TBL] [Abstract][Full Text] [Related]
36. Obinutuzumab: the more the merrier?
Burger JA
Blood; 2016 Jan; 127(1):6-8. PubMed ID: 26744434
[TBL] [Abstract][Full Text] [Related]
37. Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia.
Russell A; Yaraskavitch M; Fok D; Chhibber S; Street L; Korngut L
J Neuromuscul Dis; 2017; 4(3):251-257. PubMed ID: 28869483
[TBL] [Abstract][Full Text] [Related]
38. Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information.
Sirard C; Trehu EG
J Clin Oncol; 2008 May; 26(14):2411-2; author reply 2412-3. PubMed ID: 18467736
[No Abstract] [Full Text] [Related]
39. The use of obinutuzumab in chronic lymphocytic leukemia.
Wierda W
Clin Adv Hematol Oncol; 2014 Jun; 12(6):395-7. PubMed ID: 25003571
[No Abstract] [Full Text] [Related]
40. Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy.
Traynor K
Am J Health Syst Pharm; 2013 Dec; 70(24):2162. PubMed ID: 24296835
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]